Treatment of COVID-19 patients with the antibody itolizumab (anti-CD6)
Keywords:
COVID-19, SARS-CoV-2, Cytokine Release Syndrome, Activated-Leukocyte Cell Adhesion Molecule.Abstract
Treatment of COVID-19 patients with the antibody itolizumab (anti-CD6)Downloads
Download data is not yet available.
References
1. Roshni Menon, Brinda G David. Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. Clinical, Cosmetic and Investigational Dermatology. Pondicherry, India. 2015 [acceso: 20/03/2019]; 8:215-22. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC440773
2. Lippi G, Sanchis-Gomar F, Henry BM. COVID-19: unravelling the clinical progression of nature's virtually perfect biological wea-pon. Ann Transl Med. 2020;8(11):693. DOI: 10.21037/atm-20-3989.
3. Gore V, Kshirsagar DP, Bhat SM. Itolizumab treatment for cytokine release syndrome in moderate to severe acute respiratory distress syndrome due to COVID-19: clinical outcomes, a retrospective study. J Assoc Physicians India. 2021; 69:43-48. DOI: 10. covidwho-1161613
4. Thacker HP, Halnor D, Dhekane A, Wadhwa N, Patil S, Gandhi B, et al. An early experience of Itolizumab with best supportive care in the treatment of moderate to severe COVID-19 patients: A retrospective study. IP Indian J Immunol Respir Med.2021; 6(1):24-8. DOI: 10.18231/j.ijirm.2021.005
5. Atal S, Fatima Z. IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy? Pharmaceut Med. 2020; 34:223-31. DOI: 10.1007/s40290-020-00342-z
6. Chen X, Zhao B, Qu Y.Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin. Infect. Dis.2020; 71(8):1937-42. DOI: 10.1093/cid/ciaa449
7. Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS. IL-6: relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020; 53:13-24. DOI: 10.1016/j.cytogfr.2020.05.009
8. Steeland S, Libert C, Vandenbroucke RE. A new venue of TNF targeting. Int J Mol Sci 2018; 19:1442. DOI: 10.1016/j.cytogfr.2020.05.009
9. Stone JH, Frigault MJ, Serling-Boyd NJ. Efficacy of tocilizumab in patients hospitalized with covid-19. N Engl J Med. 2020; 383(24):2333-44. DOI: 10.1056/NEJMoa2028836
2. Lippi G, Sanchis-Gomar F, Henry BM. COVID-19: unravelling the clinical progression of nature's virtually perfect biological wea-pon. Ann Transl Med. 2020;8(11):693. DOI: 10.21037/atm-20-3989.
3. Gore V, Kshirsagar DP, Bhat SM. Itolizumab treatment for cytokine release syndrome in moderate to severe acute respiratory distress syndrome due to COVID-19: clinical outcomes, a retrospective study. J Assoc Physicians India. 2021; 69:43-48. DOI: 10. covidwho-1161613
4. Thacker HP, Halnor D, Dhekane A, Wadhwa N, Patil S, Gandhi B, et al. An early experience of Itolizumab with best supportive care in the treatment of moderate to severe COVID-19 patients: A retrospective study. IP Indian J Immunol Respir Med.2021; 6(1):24-8. DOI: 10.18231/j.ijirm.2021.005
5. Atal S, Fatima Z. IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy? Pharmaceut Med. 2020; 34:223-31. DOI: 10.1007/s40290-020-00342-z
6. Chen X, Zhao B, Qu Y.Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin. Infect. Dis.2020; 71(8):1937-42. DOI: 10.1093/cid/ciaa449
7. Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS. IL-6: relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020; 53:13-24. DOI: 10.1016/j.cytogfr.2020.05.009
8. Steeland S, Libert C, Vandenbroucke RE. A new venue of TNF targeting. Int J Mol Sci 2018; 19:1442. DOI: 10.1016/j.cytogfr.2020.05.009
9. Stone JH, Frigault MJ, Serling-Boyd NJ. Efficacy of tocilizumab in patients hospitalized with covid-19. N Engl J Med. 2020; 383(24):2333-44. DOI: 10.1056/NEJMoa2028836
Published
2023-07-24
How to Cite
1.
Casola TH, Candelario RV. Treatment of COVID-19 patients with the antibody itolizumab (anti-CD6). Rev Cubana Med Milit [Internet]. 2023 Jul. 24 [cited 2025 May 9];52(3):e02302609. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/2609
Issue
Section
Letter to the Editor
License
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.
